Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Duminuco

Showing results (41-50 of 73) with videos related to

Pageof 8
Sort By:
Leukemia|July 24, 2025
QRISK3 score is predictive of thrombotic risk in patients with myeloproliferative neoplasmsAndrea Duminuco, Raj Vaghela, Sukhraj Virdee, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 7, 2025
Inhibitor Eradication in Postpartum Acquired Haemophilia A: Real-Life Case Series and Literature ReviewGaetano Giuffrida, Uros Markovic, Stephanie Grasso, et al.
Genes|February 27, 2026
Integrating Genomic and Clinical Data in AML: Real-World Application of the Sanger Multistage ModelAndrea Duminuco, Silvia Rita Vitale, Antonella Nardo, et al.
Thrombosis Research|October 24, 2025
Prothrombotic profiles in myelofibrosis: Fibrinogen oxidation and the beneficial effects of ruxolitinibFrancesca Nencini, Enrico La Spina, Serena Borghi, et al.
Journal of Clinical Medicine|July 29, 2025
Length of Washout Period After Remission Does Not Influence Relapse Risk in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents Combined with VenetoclaxFanny Erika Palumbo, Andrea Duminuco, Laura Longo, et al.
Journal of Clinical Medicine|August 14, 2025
Does the Timing of Response Impact the Outcome of Relapsed/Refractory Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents? A Proof of Concept from a Monocentric Observational StudyErmelinda Longo, Fanny Erika Palumbo, Andrea Duminuco, et al.
JCO Precision Oncology|March 14, 2024
Investigation of Serum Albumin as a Dynamic Treatment-Specific Surrogate for Outcomes in Patients With Myelofibrosis Treated With RuxolitinibAndrew T Kuykendall, Somedeb Ball, Barbara Mora, et al.
Frontiers in Oncology|March 13, 2023
Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseasesEnrico La Spina, Sebastiano Giallongo, Cesarina Giallongo, et al.
Cancer|September 2, 2023
Efficacy and safety of tixagevimab-cilgavimab versus SARS-CoV-2 breakthrough infection in the hematological conditionsAndrea Duminuco, Antonella Nardo, Alessandra Orofino, et al.
Discover Oncology|March 11, 2026
Pericytes and mesenchymal stromal cells converge toward pro-tumor phenotypes in the tumor microenvironmentEnrico La Spina, Cesarina Giallongo, Lucia Longhitano, et al.
Pageof 8

Showing results (41-50 of 73) with videos related to

Sort By:
Pageof 8
Leukemia|July 24, 2025
QRISK3 score is predictive of thrombotic risk in patients with myeloproliferative neoplasmsAndrea Duminuco, Raj Vaghela, Sukhraj Virdee, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 7, 2025
Inhibitor Eradication in Postpartum Acquired Haemophilia A: Real-Life Case Series and Literature ReviewGaetano Giuffrida, Uros Markovic, Stephanie Grasso, et al.
Genes|February 27, 2026
Integrating Genomic and Clinical Data in AML: Real-World Application of the Sanger Multistage ModelAndrea Duminuco, Silvia Rita Vitale, Antonella Nardo, et al.
Thrombosis Research|October 24, 2025
Prothrombotic profiles in myelofibrosis: Fibrinogen oxidation and the beneficial effects of ruxolitinibFrancesca Nencini, Enrico La Spina, Serena Borghi, et al.
Journal of Clinical Medicine|July 29, 2025
Length of Washout Period After Remission Does Not Influence Relapse Risk in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents Combined with VenetoclaxFanny Erika Palumbo, Andrea Duminuco, Laura Longo, et al.
Journal of Clinical Medicine|August 14, 2025
Does the Timing of Response Impact the Outcome of Relapsed/Refractory Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents? A Proof of Concept from a Monocentric Observational StudyErmelinda Longo, Fanny Erika Palumbo, Andrea Duminuco, et al.
JCO Precision Oncology|March 14, 2024
Investigation of Serum Albumin as a Dynamic Treatment-Specific Surrogate for Outcomes in Patients With Myelofibrosis Treated With RuxolitinibAndrew T Kuykendall, Somedeb Ball, Barbara Mora, et al.
Frontiers in Oncology|March 13, 2023
Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseasesEnrico La Spina, Sebastiano Giallongo, Cesarina Giallongo, et al.
Cancer|September 2, 2023
Efficacy and safety of tixagevimab-cilgavimab versus SARS-CoV-2 breakthrough infection in the hematological conditionsAndrea Duminuco, Antonella Nardo, Alessandra Orofino, et al.
Discover Oncology|March 11, 2026
Pericytes and mesenchymal stromal cells converge toward pro-tumor phenotypes in the tumor microenvironmentEnrico La Spina, Cesarina Giallongo, Lucia Longhitano, et al.
Pageof 8